Compare Marqeta Inc (MQ) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Zimmer Biomet Holdings Inc — how do they compare? Marqeta Inc trades at $18.11 (market cap $1.82B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 9.3× Marqeta Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| MQ | ZBH | |
|---|---|---|
Market Cap | $1.82B | $16.95B |
Volume | 1,126,466 | 2,505,240 |
Sector | Technology | Health |
52-Week High | $20.32 | $103.98 |
52-Week Low | $15.04 | $79.58 |
Typical Hold Time | 44 Days | 89 Days |
Enterprise Value | $1.13B | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MQ trades at $17.44, up 2.23% today, with a bullish technical signal from moving averages. The company reported three consecutive quarterly EPS beats, with Q3 2026 results due November 3. Revenue grew to $625M in 2025, but net income was negative. Analyst consensus is mixed, with 32% buy ratings but a price target of $11.38, below the current price. Recent news includes partnerships with BVNK for stablecoin cards and Google for wallet expansions.
MQ shows operational improvement with positive cash flow in 2025, but high valuation ratios and thin margins pose risks. The stock faces headwinds from contract renewals in Q3 2026, which may slow growth. Upside depends on sustained earnings beats and successful product expansions. Investors should weigh the bullish technicals against fundamental challenges and analyst caution.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, with 2025 revenue at $8.23B, though net income margin declined to 8.56%. The stock is supported by a quarterly dividend of $0.24 and a consensus price target of $103.11, suggesting potential upside.
The outlook is mixed: strong fundamentals and analyst optimism contrast with technical weakness. Investment opportunities include consistent earnings beats and dividend income, but risks involve rising debt levels and competitive pressures in the medical technology sector. The stock's current valuation at a P/E of 21.57 appears reasonable if growth continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
